Progenics Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 43 U.S.-traded ETFs. PGNX has around 14.8M shares in the U.S. ETF market. The largest ETF holder of PGNX is the iShares Core S&P Small-Cap ETF (IJR), with approximately 5.45M shares. Investors may also find of interest that the ETF with the largest allocation to PGNX stock is Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a portfolio weight of 1.07%. On average, U.S. ETFs allocate 0.08% of PGNX to their portfolios.
Additionally, PGNX is a favorite stock for Vanilla and Growth ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with PGNX as a holding is the ALPS Medical Breakthroughs ETF (SBIO), with a return of 19.89%.